Analyst Price Target is $57.75
▲ +32.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Silk Road Medical in the last 3 months. The average price target is $57.75, with a high forecast of $66.00 and a low forecast of $50.00. The average price target represents a 32.06% upside from the last price of $43.73.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Silk Road Medical. This rating changed within the last month from a Hold consensus rating.
Silk Road Medical, Inc. develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.